Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-DFO-REGN5054
- Development stage
- Phase 1
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**89Zr-DFO-REGN5054 is a fully human monoclonal antibody radiolabeled with zirconium‑89 for use as a diagnostic radiopharmaceutical in immuno-PET imaging.** It specifically binds to the CD8α antigen on human and cynomolgus T cells, enabling noninvasive detection and quantification of CD8+ T cells (including tumor-infiltrating lymphocytes) in vivo. The antibody is conjugated to the chelator desferrioxamine (DFO) for stable attachment of zirconium‑89, allowing PET imaging to monitor immune responses during cancer immunotherapy. Preclinical studies have shown specific targeting of lymphoid tissues and minimal impact on T-cell activity, supporting its use as an imaging biomarker for assessing immune cell dynamics in patients undergoing cancer treatment. Developed by Regeneron Pharmaceuticals, it is being investigated primarily for neoplasms/solid tumors[1][2][3][5][7].
- Other names
- REGN5054REGN-5054REGN 5054
02
Targets
CD8A (T-cell surface glycoprotein CD8 alpha chain)CD8A (CD8 alpha/beta Coreceptor)
Beyond the preview
Go deeper on 89Zr-DFO-REGN5054.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-DFO-REGN5054.